International Journal of Alzheimer’s Disease / 2012 / Article / Tab 4

Review Article

Hormone Replacement Therapy and Risk for Neurodegenerative Diseases

Table 4

RCTs of ERT and Parkinson’s disease.

Study (reference)Hormone treatment usedSample SizeOutcome measureOverall findings

Blanchet [34]High-dose transdermal E2. Cross-over design with 2 weeks on E2, 2 week washout, and 2 weeks on placebo8Therapeutic threshold for levodopa.All but one participant had levodopa-induced dyskinesia at start of study. After 10 days of E2 treatment a significant reduction was observed in the anti-parkinsonian threshold dose of intravenous levodopa without significantly worsening dyskinesias.
Strijks et al. [35]17β-estradiol (E2) versus placebo for 8 weeks12Motor score from the Unified Parkinson’s Disease Rating Scale (UPDRS); patient report of subjective changes.No differences in outcome measures between E2 and placebo.
Tsang et al. [36]CEE versus placebo for 8 weeks40UPDRS, timed tapping score, Hamilton Depression Scale, patient self-report.“On” and “off” times, and motor score on the UPDRS improved with estrogen.
The Parkinson Study Group Poetry I Investigators [37]CEE versus Placebo for 8 weeks23Primary outcome was ability to complete the trial. Other outcome measures included adverse events, UPDRS, “on” time, dyskinesia ratings, and neuropsychological functioning.The estrogen group showed a trend for improvement on the total and motor UPDRS scores.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.